The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
Analysis & Context
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share. Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start . Stay informed with the latest developments and expert analysis on this important story.
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.